Table 5 The QTc interval extended during the trial
| Â | Visit 1 (HR) | Visit 4 (HR) | Visit 6 (HR) | Visit 4 vs Visit 1 | Visit 6 vs Visit 1 | Intramuscular dose | oral dose | QTc after 1Â month (HR) |
|---|---|---|---|---|---|---|---|---|
QTc interval ≥ 450 ms during the study period | 326(80) | 450(80) | 430(88) | 124 | 104 | 30 | 160 | 398(76) |
410(71) | 450(70) | 445(72) | 40 | 35 | 20 | 160 | 312(68) | |
396(82) | 457(76) | 437(76) | 61 | 41 | 20 | 120 | 348(70) | |
406(76) | 450(82) | 459(88) | 44 | 53 | 20 | 120 | 426(74) | |
446(84) | 451(84) | 453(80) | 61 | 41 | 20 | 160 | 368(75) | |
402(78) | 441(75) | 497(74) | 39 | 95 | 20 | 80 | 426(76) | |
390(78) | 400(80) | 500(70) | 10 | 110 | 20 | 120 | 358(71) | |
QTc interval was greater than the baseline level (≥ 60 ms) during the study period | 359(92) | 440(80) | 443(80) | 81 | 84 | 40 | 120 | 368(88) |
310(78) | 340(80) | 400(80) | 30 | 90 | 20 | 80 | 384(78) | |
314(84) | 357(84) | 381(76) | 43 | 67 | 20 | 80 | 338(80) | |
348(95) | 397(84) | 425(96) | 49 | 77 | 20 | 120 | 356(80) | |
321(98) | 403(96) | 400(93) | 82 | 79 | 30 | 120 | 356(93) | |
325(85) | 340(90) | 415(78) | 15 | 110 | 20 | 120 | 372(80) |